Arcellx, Inc. Insider Trading

ACLX

Last 12 months

Insiders sold $14.6M and bought nothing on the open market.

3% of the selling was scheduled in advance under 10b5-1 plans. See Remarks Rami Elghandour sold $10.2M on Feb 27, 16% of their stake, outside a plan. The last open-market buy by an executive or director was in Feb 2022.

Net open-market

−$14.6M

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Feb 2022

Feb 8, 2022

Get an email when ACLX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Feb 27	Rami Elghandour See Remarks	SoldNo plan	89,916	$113.92	$10.2M	16%	Form 4
Feb 25	Michelle Gilson Chief Financial Officer	SoldNo plan	11,219	$113.82	$1.28M	25%	Form 4
Feb 19	Michelle Gilson Chief Financial Officer	SoldNo plan 3 parts	8,384	$68.29 average	573K	16%	Form 4
Feb 17	Michelle Gilson Chief Financial Officer	SoldNo plan 2 parts	11,291	$69.50 average	785K	17%	Form 4
Jan 20	David Charles Lubner Director	Sold10b5-1 plan	6,000	$75.00	450K	22%	Form 4
Jan 14	Christopher Heery Chief Medical Officer	SoldNo plan	5,882	$68.51	403K	20%	Form 4
Jan 13	Christopher Heery Chief Medical Officer	SoldNo plan	7,437	$65.51	487K	20%	Form 4
Jan 12	Christopher Heery Chief Medical Officer	SoldNo plan	6,131	$64.15	393K	14%	Form 4
Nov 17, 2025	Christopher Heery Chief Medical Officer	Sold10b5-1 plan	340	$90.00	31K	54%	Form 4
Oct 15, 2025	Michelle Gilson Chief Financial Officer	Sold10b5-1 plan	5,364	$91.04	488K	39%	Form 4
Oct 3, 2025 – Oct 6, 2025	Michelle Gilson Chief Financial Officer	Sold10b5-1 plan 2 parts	5,946	$86.04 average	512K	30%	Form 4
Sep 30, 2025	Christopher Heery Chief Medical Officer	Sold10b5-1 plan 3 parts	21,034	$81.28 average	$1.71M	97%	Form 4
Sep 29, 2025	Christopher Heery Chief Medical Officer	Sold10b5-1 plan	73	$80.16	6K	0.3%	Form 4
Sep 26, 2025	Christopher Heery Chief Medical Officer	Sold10b5-1 plan	12,396	$80.12	993K	36%	Form 4
Sep 18, 2025 – Sep 19, 2025	Christopher Heery Chief Medical Officer	Sold10b5-1 plan 2 parts	3,643	$80.01 average	291K	9.6%	Form 4
Jun 10, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$67.36	101K	100%	Form 4
May 27, 2025	Michelle Gilson Chief Financial Officer	SoldNo plan 2 parts	12,235	$64.14 average	785K	38%	Form 4
May 20, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$58.43	88K	100%	Form 4
Apr 29, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$64.20	96K	100%	Form 4
Apr 8, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$57.50	86K	100%	Form 4
Mar 18, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$71.64	107K	100%	Form 4
Feb 26, 2025	Rami Elghandour See Remarks	SoldNo plan 3 parts	38,300	$62.03 average	$2.38M	20%	Form 4
Feb 25, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$63.16	95K	100%	Form 4
Feb 24, 2025	Christopher Heery Chief Medical Officer	SoldNo plan 3 parts	10,155	$63.79 average	648K	21%	Form 4
Feb 4, 2025	Kavita Patel Director	Sold10b5-1 plan	1,500	$64.57	97K	100%	Form 4
Jan 14, 2025	Kavita Patel Director	Sold10b5-1 plan 3 parts	1,500	$65.87 average	99K	100%	Form 4
Jan 7, 2025 – Jan 8, 2025	Christopher Heery Chief Medical Officer	SoldNo plan 2 parts	7,783	$74.69 average	581K	24%	Form 4
Jan 7, 2025 – Jan 8, 2025	Michelle Gilson Chief Financial Officer	Sold10b5-1 plan 6 parts	18,009	$75.24 average	$1.36M	65%	Form 4
Jan 7, 2025 – Jan 8, 2025	Rami Elghandour See Remarks	SoldNo plan 2 parts	30,311	$74.69 average	$2.26M	21%	Form 4
Jan 3, 2025 – Jan 6, 2025	Christopher Heery Chief Medical Officer	SoldNo plan 2 parts	5,950	$78.36 average	466K	15%	Form 4
Jan 3, 2025 – Jan 6, 2025	Michelle Gilson Chief Financial Officer	SoldNo plan 2 parts	11,243	$78.36 average	881K	29%	Form 4
Jan 3, 2025 – Jan 6, 2025	Rami Elghandour See Remarks	SoldNo plan 2 parts	30,223	$78.36 average	$2.37M	17%	Form 4
Jan 3, 2025 – Jan 6, 2025	Christopher Heery Chief Medical Officer	SoldNo plan 2 parts	6,362	$78.40 average	499K	16%	Form 4
Dec 24, 2024	Kavita Patel Director	Sold10b5-1 plan 2 parts	1,500	$76.97 average	115K	100%	Form 4
Dec 3, 2024	Kavita Patel Director	Sold10b5-1 plan 5 parts	1,500	$91.88 average	138K	100%	Form 4
Nov 15, 2024	Michelle Gilson Chief Financial Officer	Sold10b5-1 plan 4 parts	1,761	$88.87 average	157K	37%	Form 4
Nov 12, 2024	Kavita Patel Director	Sold10b5-1 plan	1,500	$106.33	159K	100%	Form 4
Nov 7, 2024 – Nov 11, 2024	Kavita Patel Director	Sold10b5-1 plan 6 parts	57,479	$103.90 average	$5.97M	100%	Form 4
Nov 8, 2024	Michelle Gilson Chief Financial Officer	Sold10b5-1 plan 3 parts	12,354	$100.55 average	$1.24M	88%	Form 4

Feb 27No plan
Rami Elghandour
See Remarks · sold 89,916 at $113.92
$10.2M
16% of stake
Feb 25No plan
Michelle Gilson
Chief Financial Officer · sold 11,219 at $113.82
$1.28M
25% of stake
Feb 19No plan
Michelle Gilson
Chief Financial Officer · sold 8,384 at avg $68.29
573K
16% of stake
Feb 17No plan
Michelle Gilson
Chief Financial Officer · sold 11,291 at avg $69.50
785K
17% of stake
Jan 2010b5-1 plan
David Charles Lubner
Director · sold 6,000 at $75.00
450K
22% of stake
Jan 14No plan
Christopher Heery
Chief Medical Officer · sold 5,882 at $68.51
403K
20% of stake
Jan 13No plan
Christopher Heery
Chief Medical Officer · sold 7,437 at $65.51
487K
20% of stake
Jan 12No plan
Christopher Heery
Chief Medical Officer · sold 6,131 at $64.15
393K
14% of stake
Nov 17, 202510b5-1 plan
Christopher Heery
Chief Medical Officer · sold 340 at $90.00
31K
54% of stake
Oct 15, 202510b5-1 plan
Michelle Gilson
Chief Financial Officer · sold 5,364 at $91.04
488K
39% of stake
Oct 3, 2025 – Oct 6, 202510b5-1 plan
Michelle Gilson
Chief Financial Officer · sold 5,946 at avg $86.04
512K
30% of stake
Sep 30, 202510b5-1 plan
Christopher Heery
Chief Medical Officer · sold 21,034 at avg $81.28
$1.71M
97% of stake
Sep 29, 202510b5-1 plan
Christopher Heery
Chief Medical Officer · sold 73 at $80.16
6K
0.3% of stake
Sep 26, 202510b5-1 plan
Christopher Heery
Chief Medical Officer · sold 12,396 at $80.12
993K
36% of stake
Sep 18, 2025 – Sep 19, 202510b5-1 plan
Christopher Heery
Chief Medical Officer · sold 3,643 at avg $80.01
291K
9.6% of stake
Jun 10, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $67.36
101K
100% of stake
May 27, 2025No plan
Michelle Gilson
Chief Financial Officer · sold 12,235 at avg $64.14
785K
38% of stake
May 20, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $58.43
88K
100% of stake
Apr 29, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $64.20
96K
100% of stake
Apr 8, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $57.50
86K
100% of stake
Mar 18, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $71.64
107K
100% of stake
Feb 26, 2025No plan
Rami Elghandour
See Remarks · sold 38,300 at avg $62.03
$2.38M
20% of stake
Feb 25, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $63.16
95K
100% of stake
Feb 24, 2025No plan
Christopher Heery
Chief Medical Officer · sold 10,155 at avg $63.79
648K
21% of stake
Feb 4, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at $64.57
97K
100% of stake
Jan 14, 202510b5-1 plan
Kavita Patel
Director · sold 1,500 at avg $65.87
99K
100% of stake
Jan 7, 2025 – Jan 8, 2025No plan
Christopher Heery
Chief Medical Officer · sold 7,783 at avg $74.69
581K
24% of stake
Jan 7, 2025 – Jan 8, 202510b5-1 plan
Michelle Gilson
Chief Financial Officer · sold 18,009 at avg $75.24
$1.36M
65% of stake
Jan 7, 2025 – Jan 8, 2025No plan
Rami Elghandour
See Remarks · sold 30,311 at avg $74.69
$2.26M
21% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Christopher Heery
Chief Medical Officer · sold 5,950 at avg $78.36
466K
15% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Michelle Gilson
Chief Financial Officer · sold 11,243 at avg $78.36
881K
29% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Rami Elghandour
See Remarks · sold 30,223 at avg $78.36
$2.37M
17% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Christopher Heery
Chief Medical Officer · sold 6,362 at avg $78.40
499K
16% of stake
Dec 24, 202410b5-1 plan
Kavita Patel
Director · sold 1,500 at avg $76.97
115K
100% of stake
Dec 3, 202410b5-1 plan
Kavita Patel
Director · sold 1,500 at avg $91.88
138K
100% of stake
Nov 15, 202410b5-1 plan
Michelle Gilson
Chief Financial Officer · sold 1,761 at avg $88.87
157K
37% of stake
Nov 12, 202410b5-1 plan
Kavita Patel
Director · sold 1,500 at $106.33
159K
100% of stake
Nov 7, 2024 – Nov 11, 202410b5-1 plan
Kavita Patel
Director · sold 57,479 at avg $103.90
$5.97M
100% of stake
Nov 8, 202410b5-1 plan
Michelle Gilson
Chief Financial Officer · sold 12,354 at avg $100.55
$1.24M
88% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ACLX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ACLX

CompareIntrinsic value

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

MGXMetagenomi, Inc.

$0.79+3.95%10

GLUEMonte Rosa Therapeutics, Inc.

$10.82+3.94%10

ACOGAlpha Cognition Inc.

$8.49+3.48%10

ALECAlector Inc.

$2.28+11.22%10

SCLXScilex Holding Company

$1.83-1.08%0

CRSPCrispr Therapeutics AG

$51.78+3.57%40

LCTXLineage Cell Therapeutics Inc.

$1.03+1.98%10

Spot a number that looks wrong? Check it in ACLX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ACLX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.